{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:10Z","timestamp":1791235390763,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yancheng Medical Technology Development Project","award":["yk20200065"],"award-info":[{"award-number":["yk20200065"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trazodone has been widely prescribed for off-label use as a sleep aid. Identifying how trazodone impacts the performance of polysomnographic sleep architecture in insomnia disorder will provide additional data that can be used to guide clinical application. To assess the efficacy of trazodone in altering the polysomnographic sleep architecture in insomnia disorder so that sleep can be facilitated. PubMed, EMBASE, Web of Science, PsycINFO, Cochrane Library, Chinese Biomedical Literature Database (SinoMed), China National Knowledge Infrastructure, Wanfang Database, and the China Science and Technology Journal Database were searched for articles published between inception and June 2022. RCTs in patients with insomnia disorder\u00a0applying trazodone in one arm of interventions at least 1 week, and reporting PSG parameters in the outcomes were eligible. RoB 2 was used to evaluate the risk of bias. The results of quality of evidence assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. When <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009&lt;\u200950%, the fixed effects model was used. When <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009\u2265\u200950%, the random effects model was used. The mean differences (MD) or standardized mean differences (SMD) and odds ratios (OR) with 95% confidence intervals (CIs) were estimated. Eleven randomized controlled trials were selected and participants were 466. Risk of bias was low in 5 trials (45.5%), and was moderate in 6 (54.5%). Compared with the control group, trazodone significantly increased total sleep time (TST, min) (MD\u2009=\u200939.88, 95% CI 14.44\u201365.32, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and non-rapid eye movement stage 3 (N3, mixed min and %) (SMD\u2009=\u20091.61, 95% CI 0.69\u20132.53, <jats:italic>P<\/jats:italic>\u2009=\u20090.0006); trazodone significantly decreased latency to onset of persistent sleep (LPS, min) (MD\u2009=\u2009\u2212\u200919.30, 95% CI\u2009\u2212\u200937.28 to\u2009\u2212\u20091.32, <jats:italic>P<\/jats:italic>\u2009=\u20090.04), non-rapid eye movement stage 1 (N1, mixed min and %) (SMD\u2009=\u2009\u2212\u20090.62, 95% CI\u2009\u2212\u20091.13 to\u2009\u2212\u20090.12, <jats:italic>P<\/jats:italic>\u2009=\u20090.02), the number of awakenings (NAs, including both arousal times and arousal index) (SMD\u2009=\u2009\u2212\u20090.67, 95% CI\u2009\u2212\u20090.91 to\u2009\u2212\u20090.42, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001), and waking time after persistent sleep onset (WASO, mixed min and %) (SMD\u2009=\u2009\u2212\u20090.42, 95% CI\u2009\u2212\u20090.81,\u2009\u2212\u20090.03, <jats:italic>P<\/jats:italic>\u2009=\u20090.04), with no obvious effect on non-rapid eye movement stage 2 (N2, mixed min and %) (SMD\u2009=\u2009\u2212\u20090.15, 95% CI\u2009\u2212\u20090.41 to 0.11, <jats:italic>P<\/jats:italic>\u2009=\u20090.25), rapid eye movement (REM, mixed min and %) (SMD\u2009=\u20090.22, 95% CI\u2009\u2212\u20090.26 to 0.70, <jats:italic>P<\/jats:italic>\u2009=\u20090.37), rapid eye movement latency (REML, min) (MD\u2009=\u20092.33, 95% CI\u2009\u2212\u200927.56 to 32.22, <jats:italic>P<\/jats:italic>\u2009=\u20090.88), or apnea\u2013hypopnea index (AHI) (MD\u2009=\u2009\u2212\u20094.21, 95% CI\u2009\u2212\u200914.02 to 5.59, <jats:italic>P<\/jats:italic>\u2009=\u20090.40). Daytime drowsiness (OR\u2009=\u20092.53, 95% CI 1.14\u20135.64, <jats:italic>P<\/jats:italic>\u2009=\u20090.02) and decreased appetite (OR\u2009=\u20092.81, 95% CI 1.14\u20136.92, <jats:italic>P<\/jats:italic>\u2009=\u20090.02) occurred with greater frequency in the trazodone group as compared to the control group, and the differences were significant. The results of quality of evidence were very low in TST, N3 and AHI, were low in LPS, WASO and REM, and were moderate in N1 and NAs. The sources of heterogeneity in TST and N3 were not found out from sensitive and subgroup analysis and there was no high quality of evidence in outcomes by GRADE Assessment. Trials with combination of other therapy could be a problem in this meta-analysis as the possibility of interactions were found from sungroup analysis. Trazodone could improve sleep by changing the sleep architecture in insomnia disorder, but it should be used with caution due to the adverse events that may occur.<\/jats:p><jats:p><jats:italic>PROSPERO registration<\/jats:italic> register name: The effect of trazodone on polysomnography sleep architecture in patients with insomnia: a systematic review and meta-analysis protocol; Registration Number CRD42020215332.<\/jats:p>","DOI":"10.1038\/s41598-022-18776-7","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T16:04:14Z","timestamp":1661357054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7688-9198","authenticated-orcid":false,"given":"Yongliang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"18776_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","volume":"6","author":"MM Ohayon","year":"2002","unstructured":"Ohayon, M. M. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med. Rev. 6, 97\u2013111. https:\/\/doi.org\/10.1053\/smrv.2002.0186 (2002).","journal-title":"Sleep Med. Rev."},{"key":"18776_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N. & Heald, J. L. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline. J. Clin. Sleep Med. 13, 307\u2013349. https:\/\/doi.org\/10.5664\/jcsm.6470 (2017).","journal-title":"J. Clin. Sleep Med."},{"key":"18776_CR3","unstructured":"Shin, J. J. & Saadabadi, A. Trazodone. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470560\/ (StatPearls, Updated 2 May 2022)."},{"key":"18776_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0014-2999(97)01393-9","volume":"340","author":"M Tatsumi","year":"1997","unstructured":"Tatsumi, M., Groshan, K., Blakely, R. D. & Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340, 249\u2013258. https:\/\/doi.org\/10.1016\/s0014-2999(97)01393-9 (1997).","journal-title":"Eur. J. Pharmacol."},{"key":"18776_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson, E. & Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68, 29\u201339. https:\/\/doi.org\/10.1016\/s0024-3205(00)00911-5 (2000).","journal-title":"Life Sci."},{"key":"18776_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/s1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl, S. M. Mechanism of action of trazodone: A multifunctional drug. CNS Spectr. 14, 536\u2013546. https:\/\/doi.org\/10.1017\/s1092852900024020 (2009).","journal-title":"CNS Spectr."},{"key":"18776_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2125.1983.tb04977.x","volume":"16","author":"I Montgomery","year":"1983","unstructured":"Montgomery, I., Oswald, I., Morgan, K. & Adam, K. Trazodone enhances sleep in subjective quality but not in objective duration. Br. J. Clin. Pharmacol. 16, 139\u2013144. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb04977.x (1983).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"18776_CR8","first-page":"41","volume":"23","author":"A Wichniak","year":"2007","unstructured":"Wichniak, A. et al. The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use. Pol Merkur Lekarski 23, 41\u201346 (2007).","journal-title":"Pol Merkur Lekarski"},{"key":"18776_CR9","first-page":"895","volume":"29","author":"L Zavesicka","year":"2008","unstructured":"Zavesicka, L. et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol. Lett. 29, 895\u2013901 (2008).","journal-title":"Neuro Endocrinol. Lett."},{"key":"18776_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","volume":"22","author":"EF Camargos","year":"2014","unstructured":"Camargos, E. F. et al. Trazodone improves sleep parameters in Alzheimer disease patients: A randomized, double-blind, and placebo-controlled study. Am. J. Geriatr. Psychiatry 22, 1565\u20131574. https:\/\/doi.org\/10.1016\/j.jagp.2013.12.174 (2014).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"18776_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2020.1767","volume":"77","author":"CM Morin","year":"2020","unstructured":"Morin, C. M. et al. Effectiveness of sequential psychological and medication therapies for insomnia disorder: A randomized clinical trial. JAMA Psychiat. 77, 1107\u20131115. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.1767 (2020).","journal-title":"JAMA Psychiat."},{"key":"18776_CR12","first-page":"24","volume":"14","author":"KY Jaffer","year":"2017","unstructured":"Jaffer, K. Y. et al. Trazodone for Insomnia: A systematic review. Innov Clin. Neurosci. 14, 24\u201334 (2017).","journal-title":"Innov Clin. Neurosci."},{"key":"18776_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sleep.2018.01.010","volume":"45","author":"XY Yi","year":"2018","unstructured":"Yi, X. Y. et al. Trazodone for the treatment of insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Med. 45, 25\u201332. https:\/\/doi.org\/10.1016\/j.sleep.2018.01.010 (2018).","journal-title":"Sleep Med."},{"key":"18776_CR14","first-page":"193","volume":"73","author":"HL Neville","year":"2020","unstructured":"Neville, H. L. et al. Point prevalence survey of benzodiazepine and sedative-hypnotic drug use in hospitalized adult patients. Can. J. Hosp. Pharm. 73, 193\u2013201 (2020).","journal-title":"Can. J. Hosp. Pharm."},{"key":"18776_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drugalcdep.2011.06.026","volume":"120","author":"MD Stein","year":"2012","unstructured":"Stein, M. D. et al. Trazodone for sleep disturbance during methadone maintenance: A double-blind, placebo-controlled trial. Drug Alcohol Depend. 120, 65\u201373. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.06.026 (2012).","journal-title":"Drug Alcohol Depend."},{"key":"18776_CR16","first-page":"2990","volume":"40","author":"LF Cao","year":"2018","unstructured":"Cao, L. F., Luo, L. H. & Fan, Y. H. Therapeutic effects of flupentixol and melitracen tablets combined with trazodone on stroke sleep disorder and their effects on bad emotion of patients. Hebei Med. J. 40, 2990\u20132992 (2018).","journal-title":"Hebei Med. J."},{"key":"18776_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fpsyt.2020.00620","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Effects of trazodone on sleep quality and cognitive function in arteriosclerotic cerebral small vessel disease comorbid with chronic Insomnia. Front. Psychiatry 11, 620. https:\/\/doi.org\/10.3389\/fpsyt.2020.00620 (2020).","journal-title":"Front. Psychiatry"},{"key":"18776_CR18","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s00415-021-10480-2","volume":"268","author":"CY Chen","year":"2021","unstructured":"Chen, C. Y., Chen, C. L. & Yu, C. C. Trazodone improves obstructive sleep apnea after ischemic stroke: A randomized, double-blind, placebo-controlled, crossover pilot study. J. Neurol. 268, 2951\u20132960. https:\/\/doi.org\/10.1007\/s00415-021-10480-2 (2021).","journal-title":"J. Neurol."},{"key":"18776_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5935\/1984-0063.20200071","volume":"14","author":"E Ghossoub","year":"2021","unstructured":"Ghossoub, E., Geagea, L., Kobeissy, F. & Talih, F. Comparative effects of psychotropic medications on sleep architecture: A retrospective review of diagnostic polysomnography sleep parameters. Sleep Sci. 14, 236\u2013244. https:\/\/doi.org\/10.5935\/1984-0063.20200071 (2021).","journal-title":"Sleep Sci."},{"key":"18776_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher, D. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 4, 1. https:\/\/doi.org\/10.1186\/2046-4053-4-1 (2015).","journal-title":"Syst. Rev."},{"key":"18776_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71. https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ"},{"key":"18776_CR22","unstructured":"Iber, C., Ancoli-Israel, S., Chesson, A. L. & Quan, S. F. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, 1st ed. Westchester, IL: American Academy of Sleep Medicine (2007)."},{"key":"18776_CR23","unstructured":"Higgins, J. P. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Cochrane, https:\/\/www.training.cochrane.org\/handbook. (Updated February 2022)."},{"key":"18776_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898. https:\/\/doi.org\/10.1136\/bmj.l4898 (2019).","journal-title":"BMJ"},{"key":"18776_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","volume":"59","author":"TA Furukawa","year":"2006","unstructured":"Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P. & Watanabe, N. Imputing missing standard deviations in meta-analyses can provide accurate results. J. Clin. Epidemiol. 59, 7\u201310. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.06.006 (2006).","journal-title":"J. Clin. Epidemiol."},{"key":"18776_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557 (2003).","journal-title":"BMJ"},{"key":"18776_CR27","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne, J. A. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343, d4002. https:\/\/doi.org\/10.1136\/bmj.d4002 (2011).","journal-title":"BMJ"},{"key":"18776_CR28","unstructured":"Li, X. M. Repetitive Transcranial Magnetic Stimulation Combined with Trazodone Treatment Diabetes Mellitus Insomniac Related Research., Vol. Dissertation for the master degree, (Zhengzhou University, 2021)."},{"key":"18776_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s0924-9338(99)80736-6","volume":"14","author":"PM Haffmans","year":"1999","unstructured":"Haffmans, P. M. & Vos, M. S. The effects of trazodone on sleep disturbances induced by brofaromine. Eur. Psychiatry 14, 167\u2013171. https:\/\/doi.org\/10.1016\/s0924-9338(99)80736-6 (1999).","journal-title":"Eur. Psychiatry"},{"key":"18776_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/01.jcp.0000085411.08426.d3","volume":"23","author":"O Le Bon","year":"2003","unstructured":"Le Bon, O. et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: Polysomnographic and clinical evaluations. J. Clin. Psychopharmacol. 23, 377\u2013383. https:\/\/doi.org\/10.1097\/01.jcp.0000085411.08426.d3 (2003).","journal-title":"J. Clin. Psychopharmacol."},{"key":"18776_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.sleep.2003.06.006","volume":"5","author":"H Kaynak","year":"2004","unstructured":"Kaynak, H., Kaynak, D., G\u00f6z\u00fckirmizi, E. & Guilleminault, C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 5, 15\u201320. https:\/\/doi.org\/10.1016\/j.sleep.2003.06.006 (2004).","journal-title":"Sleep Med."},{"key":"18776_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2869.2011.00928.x","volume":"20","author":"AJ Roth","year":"2011","unstructured":"Roth, A. J., McCall, W. V. & Liguori, A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J. Sleep Res. 20, 552\u2013558. https:\/\/doi.org\/10.1111\/j.1365-2869.2011.00928.x (2011).","journal-title":"J. Sleep Res."},{"key":"18776_CR33","first-page":"411","volume":"13","author":"HJ Zhang","year":"2013","unstructured":"Zhang, H. J., Jiang, X. F., Ma, M. M. & Zhang, J. W. A control study on treatment for benzodiazepine dependence with trazodone. Chin. J. Contemp. Neurol. Neurosurg. 13, 411\u2013415 (2013).","journal-title":"Chin. J. Contemp. Neurol. Neurosurg."},{"key":"18776_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin, L. & Chu, H. Quantifying publication bias in meta-analysis. Biometrics 74, 785\u2013794. https:\/\/doi.org\/10.1111\/biom.12817 (2018).","journal-title":"Biometrics"},{"key":"18776_CR35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.12740\/pp\/125650","volume":"55","author":"A Wichniak","year":"2021","unstructured":"Wichniak, A., Wierzbicka, A. E. & Jarema, M. Treatment of insomnia: Effect of trazodone and hypnotics on sleep. Psychiatr. Pol. 55, 743\u2013755. https:\/\/doi.org\/10.12740\/pp\/125650 (2021).","journal-title":"Psychiatr. Pol."},{"key":"18776_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.sleep.2021.02.056","volume":"81","author":"WC Yeh","year":"2021","unstructured":"Yeh, W. C. et al. The impact of antiseizure medications on polysomnographic parameters: A systematic review and meta-analysis. Sleep Med. 81, 319\u2013326. https:\/\/doi.org\/10.1016\/j.sleep.2021.02.056 (2021).","journal-title":"Sleep Med."},{"key":"18776_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3233\/jad-181145","volume":"67","author":"AL La","year":"2019","unstructured":"La, A. L. et al. Long-Term Trazodone Use and cognition: A potential therapeutic role for slow-wave sleep enhancers. J. Alzheimers Dis. 67, 911\u2013921. https:\/\/doi.org\/10.3233\/jad-181145 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"18776_CR38","first-page":"611","volume":"45","author":"M Jarema","year":"2011","unstructured":"Jarema, M. et al. Trazodon\u2013the antidepressant: Mechanism of action and its position in the treatment of depression. Psychiatr. Pol. 45, 611\u2013625 (2011).","journal-title":"Psychiatr. Pol."},{"key":"18776_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11920-017-0816-4","volume":"19","author":"A Wichniak","year":"2017","unstructured":"Wichniak, A., Wierzbicka, A., Wal\u0119cka, M. & Jernajczyk, W. Effects of antidepressants on sleep. Curr. Psychiatry Rep. 19, 63. https:\/\/doi.org\/10.1007\/s11920-017-0816-4 (2017).","journal-title":"Curr. Psychiatry Rep."},{"key":"18776_CR40","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26525","volume":"2","author":"D Nutt","year":"2006","unstructured":"Nutt, D. GABAA receptors: Subtypes, regional distribution, and function. J. Clin. Sleep Med. 2, S7-11 (2006).","journal-title":"J. Clin. Sleep Med."},{"key":"18776_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3109\/09540261.2013.812067","volume":"25","author":"A Wichniak","year":"2013","unstructured":"Wichniak, A., Wierzbicka, A. & Jernajczyk, W. Sleep as a biomarker for depression. Int. Rev. Psychiatry 25, 632\u2013645. https:\/\/doi.org\/10.3109\/09540261.2013.812067 (2013).","journal-title":"Int. Rev. Psychiatry"},{"key":"18776_CR42","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.3390\/ijerph18179248","volume":"18","author":"B Ragnoli","year":"2021","unstructured":"Ragnoli, B., Pochetti, P., Raie, A. & Malerba, M. Comorbid insomnia and obstructive sleep apnea (COMISA): Current concepts of patient management. Int. J. Environ. Res. Public Health 18, 9248. https:\/\/doi.org\/10.3390\/ijerph18179248 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"18776_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.smrv.2008.06.001","volume":"13","author":"D Riemann","year":"2009","unstructured":"Riemann, D. & Perlis, M. L. The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med. Rev. 13, 205\u2013214. https:\/\/doi.org\/10.1016\/j.smrv.2008.06.001 (2009).","journal-title":"Sleep Med. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18776-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18776-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18776-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T16:12:27Z","timestamp":1661357547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18776-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18776"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18776-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14453"}}